TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II/III Randomized Controlled Trial of Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin for Recurrent Clostridium Difficile Infection (CDI)
Brief Summary: Recurrent CDI is a growing problem with few treatment options that provide lasting effect. Fecal transplantation has been shown in several case series to be successful in controlling recurrent CDI. The current study is a non-blinded, randomized controlled trial comparing fecal transplantation with a 6 week taper of oral vancomycin for the treatment of refractory CDI. Approximately 146 patients will be enrolled over one year. Participants in the study will be followed for 120 days, and will be given the opportunity to cross over to the alternative intervention arm if a relapse in symptoms occurs. The primary outcome measure will be recurrence of toxin-confirmed CDI within 120 days of starting the intervention. Secondary outcomes include: early recurrence of symptoms within 14 days, relapse within 120 days (same strain of C. difficile), attributable mortality, hospitalization and serious adverse events.


Options:
A: Arm Label: Fresh FMT; Type: EXPERIMENTAL; Interventions: Biological: Fresh FMT | Arm Label: Frozen-and-Thawed FMT; Type: EXPERIMENTAL; Interventions: Biological: Frozen-and-Thawed FMT | Intervention Type: BIOLOGICAL; Name: Fresh FMT; Assigned to Arm(s): Fresh FMT | Intervention Type: BIOLOGICAL; Name: Frozen-and-Thawed FMT; Assigned to Arm(s): Frozen-and-Thawed FMT
B: Arm Label: Delivery via capsule; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplant | Arm Label: Delivery via colonoscopy; Type: EXPERIMENTAL; Interventions: Biological: Fecal Microbiota Transplant | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplant; Assigned to Arm(s): Delivery via capsule, Delivery via colonoscopy
C: Arm Label: Fecal Microbiota Transplantation; Type: ACTIVE_COMPARATOR; Interventions: Biological: Fecal Microbiota Transplantation | Arm Label: Sham Fecal Microbiota Transplantation; Type: SHAM_COMPARATOR; Interventions: Biological: Sham Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Fecal Microbiota Transplantation; Assigned to Arm(s): Fecal Microbiota Transplantation | Intervention Type: BIOLOGICAL; Name: Sham Fecal Microbiota Transplantation; Assigned to Arm(s): Sham Fecal Microbiota Transplantation
D: Arm Label: Fecal Transplant; Type: EXPERIMENTAL; Interventions: Biological: Fecal Transplant | Arm Label: Oral Vancomycin Taper; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vancomycin | Intervention Type: DRUG; Name: Vancomycin; Assigned to Arm(s): Oral Vancomycin Taper | Intervention Type: BIOLOGICAL; Name: Fecal Transplant; Assigned to Arm(s): Fecal Transplant

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects With Moderate-to-severe Chronic Obstructive Pulmonary Disease and Sputum Eosinophilia
Brief Summary: To evaluate the effect of the drug in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) in Adults.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Benralizumab 100 mg; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): Benralizumab 100 mg
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Arm 3
C: Arm Label: COPD subjects; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Arm Label: Non-smoker controls; Type: N/A; Interventions: Other: Novel endpoint determination | Intervention Type: OTHER; Name: Novel endpoint determination; Assigned to Arm(s): COPD subjects, Non-smoker controls, Smoker controls
D: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm A | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Drug: Benralizumab Arm B | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Benralizumab Arm A; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: DRUG; Name: Benralizumab Arm B; Assigned to Arm(s): Benralizumab Arm B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
Brief Summary: This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as measured by progression free survival at 6 months) in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb positive. A total of 30 patients will be treated; 15 will undergo a planned surgical resection and receive drug for 7 days prior to surgery, followed by drug after recovery from surgery, and the other 15 patients will receive drug without a planned surgical procedure.


Options:
A: Arm Label: ABT-414/temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin, Drug: Temozolomide | Arm Label: ABT-414_adult; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Arm Label: Control_lomustine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lomustine | Arm Label: Control_ temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Arm Label: ABT-414_ pediatric; Type: EXPERIMENTAL; Interventions: Drug: Depatuxizumab mafodotin | Intervention Type: DRUG; Name: Depatuxizumab mafodotin; Assigned to Arm(s): ABT-414/temozolomide, ABT-414_ pediatric, ABT-414_adult | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ABT-414/temozolomide, Control_ temozolomide | Intervention Type: DRUG; Name: Lomustine; Assigned to Arm(s): Control_lomustine
B: Arm Label: Carbon Ion Radiotherapy; Type: EXPERIMENTAL; Interventions: Radiation: Carbon Ion Radiotherapy | Arm Label: Standard Treatment: Fractionated Stereotacitc Radiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Fractionated Stereotactic Radiotherapy (FSRT) | Intervention Type: RADIATION; Name: Carbon Ion Radiotherapy; Assigned to Arm(s): Carbon Ion Radiotherapy | Intervention Type: RADIATION; Name: Fractionated Stereotactic Radiotherapy (FSRT); Assigned to Arm(s): Standard Treatment: Fractionated Stereotacitc Radiotherapy
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: VB-111 + bevacizumab | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Intervention Type: DRUG; Name: VB-111 + bevacizumab; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2
D: Arm Label: Surgical Group; Type: EXPERIMENTAL; Interventions: Drug: PD 0332991 (pre-surgery), Drug: PD 0332991, Procedure: Resection as clinical care | Arm Label: Non-surgical group; Type: EXPERIMENTAL; Interventions: Drug: PD 0332991 | Intervention Type: DRUG; Name: PD 0332991 (pre-surgery); Assigned to Arm(s): Surgical Group | Intervention Type: DRUG; Name: PD 0332991; Assigned to Arm(s): Non-surgical group, Surgical Group | Intervention Type: PROCEDURE; Name: Resection as clinical care; Assigned to Arm(s): Surgical Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder
Brief Summary: The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: RO5028442 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: RO5028442; Assigned to Arm(s): 1
B: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): Placebo
C: Arm Label: Bumetanide; Type: EXPERIMENTAL; Interventions: Drug: bumetanide | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: bumetanide | Intervention Type: DRUG; Name: bumetanide; Assigned to Arm(s): Bumetanide, Control
D: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder
Brief Summary: The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of Aripiprazole | Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Intervention Type: DRUG; Name: Placebo of Aripiprazole; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole
B: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: D-cycloserine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Lurasidone 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone 20 mg daily | Arm Label: Lurasidone 60 mg; Type: EXPERIMENTAL; Interventions: Drug: Lurasidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lurasidone 20 mg daily; Assigned to Arm(s): Lurasidone 20 mg | Intervention Type: DRUG; Name: Lurasidone; Assigned to Arm(s): Lurasidone 60 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder
Brief Summary: The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo


Options:
A: Arm Label: Arbaclofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Arbaclofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Arbaclofen; Assigned to Arm(s): Arbaclofen | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Intranasal Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Intranasal Oxytocin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety and Efficacy of Aripiprazole in the Long-term Maintenance Treatment of Pediatric Patients With Irritability Associated With Autistic Disorder
Brief Summary: The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when continuing therapy with aripiprazole than will participants who receive placebo


Options:
A: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: A3; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: B1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): A1, A2, A3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B1
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3
C: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group
D: Arm Label: Aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): Aripiprazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Open-label Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
Brief Summary: BRF113683 is a Phase III, randomized, open-label study comparing the efficacy, safety, and tolerability of GSK2118436 to dacarbazine (DTIC), in subjects with BRAF mutant advanced (Stage III) or metastatic (Stage IV) melanoma. Subjects will be randomized to receive 150 mg of GSK2118436 twice daily or 1000 mg/m2 DTIC every 3 weeks and continue on treatment until disease progression, death, or unacceptable adverse event. Subjects who progress on DTIC will be allowed to crossover to an optional extension arm of the study to receive GSK2118436.


Options:
A: Arm Label: Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Arm Label: Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: KLH | Arm Label: Group 2 and 2C: Refractory to Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Rindopepimut (CDX-110) with GM-CSF | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control, Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut., Group 2 and 2C: Refractory to Bevacizumab | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
C: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A
D: Arm Label: GSK2118436; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Arm Label: Dacarbazine (DTIC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine (DTIC) | Arm Label: Crossover; Type: EXPERIMENTAL; Interventions: Drug: GSK2118436 | Intervention Type: DRUG; Name: GSK2118436; Assigned to Arm(s): Crossover, GSK2118436 | Intervention Type: DRUG; Name: Dacarbazine (DTIC); Assigned to Arm(s): Dacarbazine (DTIC)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study to Evaluate Efficacy and Safety of Pazopanib Monotherapy in Asian Women Who Have Not Progressed After First-line Chemotherapy for Advanced Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma - An Extension Study to VEG110655
Brief Summary: This is a study to determine whether therapy with pazopanib is effective and safe in Asian women with epithelial ovarian, fallopian tube or primary peritoneal cancer whose cancer has not progressed on first-line chemotherapy.


Options:
A: Arm Label: vargatef/Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: vargatef | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vargatef; Assigned to Arm(s): vargatef/Nintedanib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
C: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination
D: Arm Label: pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Brief Summary: RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells.

PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain metastases.


Options:
A: Arm Label: WBRT with Hippocampal Avoidance; Type: OTHER; Interventions: Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): WBRT with Hippocampal Avoidance
B: Arm Label: Brain Training; Type: EXPERIMENTAL; Interventions: Behavioral: Brain Training Program | Arm Label: Brain Health; Type: EXPERIMENTAL; Interventions: Behavioral: Brain Health Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Brain Training Program; Assigned to Arm(s): Brain Training | Intervention Type: BEHAVIORAL; Name: Brain Health Program; Assigned to Arm(s): Brain Health
C: Arm Label: Group A (Crossover Group 1); Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Arm Label: Group B (Crossover Group 2); Type: EXPERIMENTAL; Interventions: Drug: Metformin, Drug: Placebo | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Group A (Crossover Group 1), Group B (Crossover Group 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group A (Crossover Group 1), Group B (Crossover Group 2)
D: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Drug: armodafinil 150 mg | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Arm III; Type: EXPERIMENTAL; Interventions: Drug: armodafinil 250 mg | Intervention Type: DRUG; Name: armodafinil 150 mg; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Arm II | Intervention Type: DRUG; Name: armodafinil 250 mg; Assigned to Arm(s): Arm III

Answer: A